Shuttle Pharma closes $4.5M public offering of stock and warrants for clinical trials

Shuttle Pharmaceuticals Holdings, Inc.

Gross proceeds of ~$4.5M from 395,574 shares, 2.55M pre-funded warrants, 2.95M common warrants at $1.525/unit.
Proceeds primarily for IND-enabling and Phase I/II trials, including $2.3M to Theradex for Ropidoxuridine Phase II.
Common warrants exercisable at $1.40 per share, 5-year term; pre-funded warrants at $0.001 per share.
Placement agents A.G.P./Alliance Global Partners and Boustead Securities, with 9% aggregate cash fee.
Post-closing shares outstanding: 3,341,673 (excluding warrants).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.